IMMUNIC, INC.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
IMUX$7.96+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBITS
| Incorporated by Reference | ||||
|---|---|---|---|---|
| ExhibitNumber | Exhibit Title | Form | Exhibit | Filing Date |
| 1.1 | Underwriting Agreement | 8-K | 1.1 | May 30, 2025 |
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 3.1 | July 17, 2019 |
| 3.2 | Third Amended and Restated Bylaws. | 8-K | 3.1 | July 17, 2019 |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Immunic, Inc. | 8-K | 3.1 | March 8, 2024 |
| 3.4 | Certificate of Amendment to the Certificate of Incorporation, as ammended and restated, dated April 22, 2026 | 8-K | 3.1 | April 23, 2026 |
| 4.1 | 2019 Omnibus Equity Incentive Plan, as amended, | S-8 | 4.2 | August 21, 2023 | ||
| 4.2+ | Amended and Restated 2021 Employee Stock Purchase Plan. | S-8 | 10.3 | July 28, 2021 | ||
| 4.4 | Form of Pre-Funded Warrant | 8-K | 4.1 | January 4, 2024 | ||
| 4.5 | Form of Placement Agent Warrant | 8-K | 4.1 | April 9, 2025 | ||
| 4.6 | Form of Pre-funded Warrant | 8-K | 4.1 | May 30, 2025 | ||
| 4.7 | Form of Series A Warrant | 8-K | 4.2 | May 30, 2025 | ||
| 4.8 | Form of Series B Warrant | 8-K | 4.3 | May 30, 2025 | ||
| 4.9 | Form of Pre-funded Warrant | 8-K | 4.1 | February 13, 2026 | ||
| 4.10 | Form of Common Warrant | 8-K | 4.2 | February 13, 2026 | ||
| 10.1+ | Addendum No. 6, dated August 29, 2024, to Employment Agreement, dated April 17, 2020, between Immunic, Inc. and Duane Nash. | 8-K | 10.1 | September 3, 2024 | ||
| 10.2+ | Employment Agreement, dated December 18, 2023, between Immunic, Inc. and Dr. Andreas Muehler. | 8-K | 10.3 | December 18, 2023 | ||
| 10.3 | Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Daniel Vitt. | 8-K | 10.1 | December 18, 2023 | ||
| 10.4 | Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Andreas Muehler. | 8-K | 10.2 | December 18, 2023 | ||
| 10.5 | Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Hella Kohlhof. | 8-K | 10.4 | December 18, 2023 | ||
| 10.6 | Securities Purchase Agreement, dated January 4, 2024, by and among the Company and the Investors. | 8-K | 10.1 | January 4, 2024 | ||
| 10.7 | Form of Indemnification Agreement. | 8-K | 10.4 | July 17, 2019 | ||
| 10.8 | Service Agreement, dated August 22, 2016, between Immunic AG and Dr. Andreas Muehler. | 10-K | 10.5 | February 23, 2023 | ||
| 10.9 | Service Agreement, dated September 29, 2016, between Immunic AG and Daniel Vitt. | 10-K | 10.6 | February 23, 2023 | ||
| 10.10+ | Employment Agreement between Dr. Daniel Vitt and Immunic AG. | 8-K | 10.5 | July 17, 2019 | ||
| 10.11+ | Employment Agreement, dated September 4, 2019, between Immunic, Inc. and Dr. Andreas Muehler. | 8-K | 99.3 | September 5, 2019 | ||
| 10.12+ | Employment Agreement dated April 17, 2020, between Immunic, Inc. and Duane Nash. | 8-K | 10.2 | April 20, 2020 | ||
| 10.13+ | Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Dr. Andreas Muehler | 8-K | 10.3 | June 10, 2021 | ||
| 10.14+ | Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Glenn Whaley | 8-K | 10.4 | June 10, 2021 | ||
| 10.15+ | Employment Agreement, dated October 14, 2021, between Immunic, Inc. and Patrick Walsh | 8-K | 10.1 | October 14, 2021 | ||
| 10.16+ | Employee Agreement, dated July 9, 2024, between Immunic, Inc. and Jason Tardio | 10-Q | 10.16 | August 8, 2024 | ||
| 10.17 | Employment agreement dated December 13, 2024, between Immunic, Inc. and Dr. Daniel Vitt | 8-K | 10.1 | December 18, 2024 | ||
| 10.18 | Amended and Restated 2021 Employee Stock Purchase Plan | S-8 | 4.4 | July 2, 2024 | ||
| 10.19 | 2019 Omnibus Equity Incentive Plan, as amended | 8-K | 10.1 | June 4, 2025 | ||
| 10.20 | Form of Placement Agency Agreement | 8-K | 10.1 | April 9, 2025 | ||
| 10.21 | Form of Securities Purchase Agreement | 8-K | 10.2 | April 9, 2025 | ||
| 10.22 | Employment Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Duane Nash. | Employment Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Duane Nash. | 8-K | 10.1 | January 5, 2026 | |
| 10.23 | Employment Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Daniel Vitt. | Employment Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Daniel Vitt. | 8-K | 10.2 | January 5, 2026 | |
| 10.24 | Addendum to Service Agreement, dated December 29, 2025, between Immunic AG and Dr. Daniel Vitt. | 8-K | 10.3 | January 5, 2026 |
| 10.25 | Form of Securities Purchase Agreement, dated February 12, 2026 by and among Immunic, Inc. and the purchasers named therein. | 8-K | 10.1 | February 13, 2026 | |
| 10.26 | Form of Registration Rights Agreement, dated February 12, 2026 by and among Immunic, Inc. and the holders named therein. | 8-K | 10.2 | February 13, 2026 | |
| 10.27 | Form of Purchase and Sale Agreement, dated February 12, 2026 by and amongImmunic, Inc., the holders named therein, and BVF Partners, L.P. | Form of Purchase and Sale Agreement, dated February 12, 2026 by and among Immunic, Inc., the holders named therein, and BVF Partners, L.P. | 8-K | 10.3 | February 13, 2026 |
| 10.28 | 2026 Inducement Plan | S-8 | 99.1 | April 9, 2026 | |
| 10.29+ | Retention Bonus Agreement, dated as of April 7, 2026, by and between Daniel Vitt and Immunic, Inc. | 8-K | 10.1 | April 10, 2026 | |
| 10.30+ | Employment Agreement, dated April 24, 2026, by and between Immunic, Inc. and Michael A. Panzara | 8-K | 10.1 | April 28, 2026 | |
| 10.31+ | Transition, Separation, and Consulting Agreement, dated April 27, 2026, between Immunic, Inc. and Andreas Rolf Muehler | 8-K | 10.2 | April 28, 2026 | |
| 31.1* | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1** | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2** | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101.INS* | XBRL Instance Document | ||||
| 101.SCH* | XBRL Taxonomy Extension Schema Document. | ||||
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document. | ||||
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase Database. | ||||
| 101.LAB* | XBRL Taxonomy Extension Label Linkbase Document. | ||||
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document. | ||||
| 104* | Cover Page Interactive Data File | ||||
| + | Indicates a management contract or compensatory plan or arrangement. |
|---|---|
| * | Filed herewith |
| ** | In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 13, 2026 By:/s/ Daniel Vitt
Daniel Vitt
Chief Executive Officer
(Principal Executive Officer)
Date: May 13, 2026 By:/s/ Glenn Whaley
Glenn Whaley
Chief Financial Officer
(Principal Financial Officer and Principal
Accounting Officer)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.